Study Data from Koch Institute for Integrative Cancer Research Update Understanding of Chemotherapy (A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways)
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating in Cambridge, Massachusetts, by NewsRx journalists, research stated, "Exposure to the EGFR (epidermal growth factor receptor) inhibitor erlotinib promotes the dynamic rewiring of apoptotic pathways, which sensitizes cells within a specific period to subsequent exposure to the DNA-damaging agent doxorubicin. A critical challenge for translating this therapeutic network rewiring into clinical practice is the design of optimal drug delivery systems."
The news reporters obtained a quote from the research from Koch Institute for Integrative Cancer Research, "We report the generation of a nanoparticle delivery vehicle that contained more than one therapeutic agent and produced a controlled sequence of drug release. Liposomes, representing the first clinically approved nanomedicine systems, are well-characterized, simple, and versatile platforms for the manufacture of functional and tunable drug carriers. Using the hydrophobic and hydrophilic compartments of liposomes, we effectively incorporated both hydrophobic (erlotinib) and hydrophilic (doxorubicin) small molecules, through which we achieved the desired time sequence of drug release. We also coated the liposomes with folate to facilitate targeting to cancer cells."
According to the news reporters, the research concluded: "When compared to the time-staggered application of individual drugs, staggered release from tumor-targeted single liposomal particles enhanced dynamic rewiring of apoptotic signaling pathways, resulting in improved tumor cell killing in culture and tumor shrinkage in animal models."
For more information on this research see: A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Science Signaling, 2014;7(325):ra44 (see also Drugs and Therapies).
Our news correspondents report that additional information may be obtained by contacting S.W. Morton, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139 USA. Dept. of Chemical Engineering, MIT, Cambridge, MA 02139, United States. Additional authors for this research include M.J. Lee, Z.J. Deng, E.C. Dreaden, E. Siouve, K.E. Shopsowitz, N.J. Shah, M.B. Yaffe and P.T Hammond.
Keywords for this news article include: Cambridge, Massachusetts, United States, North and Central America, Chemotherapy, Drugs, Drugs and Therapies, Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC